| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Anticancer agent 314 (compound 13n) can effectively inhibit recombinant human tumor-associated carbonic anhydrase isoenzymes hCA IX (Ki = 27.1 nM) and hCA XII (Ki = 20.9 nM) [1]. Anticancer agent 314 (1.5-100 μM) can effectively inhibit cell-free microtubule polymerization, with an IC50 value of 6.35 μM [1]. Anticancer agent 314 (0.01-100 μM) showed broad-spectrum antiproliferative activity against the NCI-60 human tumor cell line, with a GI50 value ranging from 2.48 to 31.00 μM [1]. Anticancer agent 314 showed low cytotoxicity against WI-38 normal human lung fibroblasts, with an IC50 value of 68.62 μM [1]. The anticancer drug 314 (6.35 μM; 24 h) effectively arrested the cell cycle of MCF-7 human breast cancer cells in the G2/M phase, increasing the proportion of cells in the G2/M phase to 31.97% [1]. The anticancer drug 314 (6.35 μM; 24 h) induced strong apoptosis in MCF-7 human breast cancer cells, increasing the total proportion of apoptotic cells to 24.68% [1]. The anticancer drug 314 (6.35 μM; 24 h) activated the p53-dependent apoptosis pathway in MCF-7 human breast cancer cells, increasing the levels of p53, Bax and activated caspase-7, while decreasing the level of Bcl-2 [1].
|
|---|---|
| Cell Assay |
Cell cycle analysis [1]
Cell Types: MCF-7 human breast cancer cells Tested Concentrations: 6.35 μM Incubation Duration: 24 hours Experimental Results: The proportion of G2/M phase cells increased from 13.81% (control group) to 31.97% (treatment group). The proportion of G0/G1 phase cells decreased from 63.58% to 52.76%. The proportion of S phase cells decreased from 22.61% to 15.27%. Apoptosis analysis [1] Cell Types: MCF-7 human breast cancer cells Tested Concentrations: 6.35 μM Incubation Duration: 24 hours Experimental Results: The total apoptotic cell percentage increased from 0.67% (control group) to 24.68% (treatment group), of which early apoptotic cells accounted for 9.51% and late apoptotic cells accounted for 15.17%. ELISA detection [1] Cell Types: MCF-7 human breast cancer cells Tested Concentrations: 6.35 μM Incubation Duration: 24 hours Experimental Results: Compared with the control group, p53 protein level increased by 3.43 times. Compared with the control group, Bax level increased by 12.34 times. Compared with the control group, Bcl-2 level decreased by 4.37 times. Compared with the control group, caspase-7 activation was enhanced by 7.35 times. |
| References |
| Molecular Formula |
C22H16N6O4S
|
|---|---|
| Molecular Weight |
460.47
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
CC1=NN2C(C3=CC4=C(OC3=O)C=CC=C4)=CC=NC2=C1/N=N/C5=CC=C(C=C5)S(N)(=O)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1717 mL | 10.8585 mL | 21.7169 mL | |
| 5 mM | 0.4343 mL | 2.1717 mL | 4.3434 mL | |
| 10 mM | 0.2172 mL | 1.0858 mL | 2.1717 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
